Gomekli (mirdametinib) drug introduction

Gomekli (generic name: mirdametinib) is an oral MEK1/2 inhibitor, mainly used to treat nerve fibers. Patients with fibromatosis type 1 (NF1), especially those with symptomatic, unresectable plexiform neurofibromas (PN) in adults and children 2 years of age and older.

mirdametinib blocks the intracellular MAPK signaling pathway by inhibiting the activity of MEK1 and MEK2, thereby inhibiting cell proliferation and tumor growth.

EN.WIKIPEDIA.ORGIn a multicenter, single-arm clinical trial called ReNeu, 114patients aged 2 years and older received mirdametinib. The results showed that the overall response rate was 41% in adult patients and 52% in pediatric patients, indicating that the drug has significant efficacy in reducing PN volume and improving patient symptoms.

Common adverse reactions include rash, diarrhea, nausea, musculoskeletal pain, vomiting and fatigue. In pediatric patients, symptoms such as abdominal pain, headache, and paronychia have also been observed. In addition, common grade 3 or grade 4 abnormalities in laboratory tests include neutropenia and elevated creatine phosphokinase. It is worth noting that mirdametinib may cause serious adverse reactions such as left ventricular dysfunction and retinal vein occlusion, so the patient's heart and vision conditions need to be closely monitored during treatment.

2025 In February2, the U.S. Food and Drug Administration (FDA) approved the marketing application of Gomekli, making it the successor to selumetinibAfter that, another MEK inhibitor was used to treat NF1related PN.

Currently,Gomekli is available in the United States, but availability in other countries and regions may vary. Patients should consult their local healthcare provider or professional for information on the availability and use of this medication.

Reference materials: https://www.gomekli.com/